ライフサイエンスコーパス: urothelial carcinoma

1 losely resembled that of the human low-grade urothelial carcinoma.

2 , biopsy of which showed invasive high-grade urothelial carcinoma.

3 n patients with platinum-refractory advanced urothelial carcinoma.

4 treatment of unfit patients with metastatic urothelial carcinoma.

5 -line treatment for patients with metastatic urothelial carcinoma.

6 erapeutic treatment option for patients with urothelial carcinoma.

7 a useful therapeutic target in some cases of urothelial carcinoma.

8 ases were found in 15.8% of the animals with urothelial carcinoma.

9 equenced several diagnostic polypeptides for urothelial carcinoma.

10 cinoma of the urinary bladder and concurrent urothelial carcinoma.

11 fine the optimal regimen of chemotherapy for urothelial carcinoma.

12 days in patients with untreated, metastatic urothelial carcinoma.

13 erated regimen for the treatment of advanced urothelial carcinoma.

14 le-agent cisplatin in patients with advanced urothelial carcinoma.

15 FX) is an agent as yet unstudied in advanced urothelial carcinoma.

16 ly cisplatin-pretreated cohort with advanced urothelial carcinoma.

17 ting agents have modest activity in advanced urothelial carcinoma.

18 h platinum-refractory advanced or metastatic urothelial carcinoma.

19 patients with locally advanced or metastatic urothelial carcinoma.

20 igation of nivolumab monotherapy in advanced urothelial carcinoma.

21 patients with locally advanced or metastatic urothelial carcinoma.

22 patients with locally advanced or metastatic urothelial carcinoma.

23 response to this class of agents in advanced urothelial carcinoma.

24 ed carcinoma-in-situ to high-grade papillary urothelial carcinoma.

25 body, in patients with refractory metastatic urothelial carcinoma.

26 adenectomy for patients with muscle-invasive urothelial carcinoma.

27 may inform the progression and treatment of urothelial carcinoma.

28 s with metastatic or surgically unresectable urothelial carcinoma.

29 variably lost during progression to invasive urothelial carcinoma.

30 nd survivin in patients with stage Ta and T1 urothelial carcinomas.

31 gene that suppresses growth of prostate and urothelial carcinomas.

32 mages are essential for helping detect small urothelial carcinomas.

33 GRE MR urography helped detect 74% of small urothelial carcinomas.

34 in 38% (17/47) of specimens with high-grade urothelial carcinomas.

35 or addition to other agents with activity in urothelial carcinomas.

36 per tract; 2 of them with additional bladder urothelial carcinomas.

37 interest in the role of Wnt/beta-catenin in urothelial carcinomas.

38 iptase (TERT) gene in 66% of muscle-invasive urothelial carcinomas.

39 atures for outcome prediction in stage Ta/T1 urothelial carcinomas.

40 enign tissue and in specimens with low-grade urothelial carcinoma (0/23).

41 o a masked group containing 31 patients with urothelial carcinoma, 11 healthy individuals, and 138 pa

42 The incidence for bladder urothelial carcinoma, a common malignancy of the urinary

43 patients with platinum-refractory metastatic urothelial carcinoma; a manageable safety profile was re

44 We recently defined molecular subtypes of urothelial carcinomas according to whole genome gene exp

45 patients with locally advanced or metastatic urothelial carcinoma after progression with platinum-bas

46 terns from urine samples of 46 patients with urothelial carcinoma and 33 healthy volunteers.

47 is clonally enriched in chemotherapy-treated urothelial carcinoma and continues to shape the evolutio

48 oprotein, is associated with poor outcome in urothelial carcinoma and contributes to experimental tum

49 or therapeutic use of avelumab in metastatic urothelial carcinoma and it has received accelerated US

50 as a tumor-suppressor gene in urinary tract urothelial carcinoma and may be an innovative co-targeti

51 ntext of bladder cancer, upper urinary tract urothelial carcinoma and renal cell carcinoma with focus

52 e from chemotherapy directs the evolution of urothelial carcinoma and shapes its clonal architecture

53 However, greater understanding of urothelial carcinoma and solid tumor biology has resulte

54 r the PI3K/AKT pathway in the development of urothelial carcinoma and suggested that inhibitors of th

55 role of COX-2 in the progression of bladder urothelial carcinoma and supporting its potential as a t

56 Despite a high prevalence of urothelial carcinoma and the risk of bladder carcinoma,

57 egregation, in 36% of papillary non-invasive urothelial carcinomas and 16% of invasive urothelial car

58 rs different tumor biology than that of pure urothelial carcinoma, and if this difference translates

59 xclusion criteria were obstructive uropathy, urothelial carcinoma, and metastatic cancer.

60 large proportion of patients with metastatic urothelial carcinoma are considered "unfit" for cisplati

61 The majority of targeted agents studied in urothelial carcinoma are in the second-line setting; new

62 ons, infections, and cancers with a focus on urothelial carcinomas, are reported.

63 cribed in the last year include soluble Fas, urothelial carcinoma-associated 1 and human chorionic go

64 he ICG pHLIP imaging agent marked high-grade urothelial carcinomas, both muscle invasive and nonmuscl

65 identified in various tumor types including urothelial carcinoma, but the ubiquitous presence of BKV

66 enhance chemotherapeutic response of bladder urothelial carcinomas by abrogating early tumour repopul

67 trated that FGFR1 expression is increased in urothelial carcinoma cell lines and tumors, which promot

68 we examined splice variants of FGFR1 in both urothelial carcinoma cell lines and tumors.

69 transformed human urothelial cells and many urothelial carcinoma cell lines exhibit constitutive HH

70 ceptor knockdown in UM-UC-3 and TCCSUP human urothelial carcinoma cell lines resulted in suppression

71 Knockdown of FGFR1 in urothelial carcinoma cell lines revealed differential FG

72 H1, the constitutive HH activity observed in urothelial carcinoma cell lines was HH ligand dependent.

73 the difference in intrinsic HH dependence of urothelial carcinoma cell lines, a gene expression signa

74 -immortalized normal human urothelial cells, urothelial carcinoma cell lines, and tumor samples and s

75 elial cells and from low-grade to high-grade urothelial carcinoma cell lines, whereas alternatively s

76 that inhibits normal bladder epithelial and urothelial carcinoma cell proliferation.

77 issues and promotes motility and invasion of urothelial carcinoma cells.

78 dependent signaling and motility of invasive urothelial carcinoma cells.

79 es that have been reported or are in ongoing urothelial carcinoma clinical trials, and highlight mole

80 Many urothelial carcinomas contain activating point mutations

81 ole of the IGF-IR in bladder cancer by using urothelial carcinoma-derived 5637 and T24 cells.

82 model for investigating sexual dimorphism in urothelial carcinoma development, and implicated synergy

83 secutive adults with metastatic, progressive urothelial carcinoma enrolled in a National Cancer Insti

84 Correct identification of patients with urothelial carcinoma from those with other malignant and

85 sue microarrays with 693 non-muscle invasive urothelial carcinomas from Danish, Swedish, and Spanish

86 microarrays (TMAs) with a total of 859 Ta/T1 urothelial carcinomas from Danish, Swedish, Spanish, and

87 Chemotherapy-resistant urothelial carcinoma has no uniformly curative therapy.

88 Patients with metastatic urothelial carcinoma have a dismal prognosis and few tre

89 Multimodal paradigms for muscle-invasive urothelial carcinoma have demonstrated favorable clinica

90 Patients with metastatic urothelial carcinoma have few treatment options after fa

91 investigating changes in gene expression in urothelial carcinoma have generally compared tumors of d

92 Non-invasive methods for diagnosis of urothelial carcinoma have reduced specificity in patient

93 64, 95% confidence interval: 2.92, 7.38) and urothelial carcinoma (hazard ratio = 2.02, 95% confidenc

94 le-agent cisplatin in patients with advanced urothelial carcinoma; however, durable progression-free

95 very early events in the natural history of urothelial carcinoma; (iii) chemotherapy-treated urothel

96 n of a highly specific biomarker pattern for urothelial carcinoma in a large group of patients with v

97 roximately 50% of the deadly muscle-invasive urothelial carcinomas in humans and urothelial carcinoma

98 characterized papillary and flat noninvasive urothelial carcinomas, including 28 pTa low-grade transi

99 ureterectomy, disclosing residual high-grade urothelial carcinoma infiltrating the full thickness of

100 sy identified transitional cell carcinoma or urothelial carcinoma invading the muscularis propria of

101 Upper urinary tract urothelial carcinoma is a relatively uncommon disease an

102 in-ineligible locally advanced or metastatic urothelial carcinoma is associated with short response d

103 d several insights: (i) chemotherapy-treated urothelial carcinoma is characterized by intra-patient m

104 helial carcinoma; (iii) chemotherapy-treated urothelial carcinoma is enriched with clonal mutations i

105 understanding of the biology and genetics of urothelial carcinoma is helping to identify and define t

106 Urothelial carcinoma is now recognized as a disease of a

107 Development of targeted therapies for urothelial carcinoma is still in early stages, consequen

108 Urothelial carcinoma is the most common type of bladder

109 invasive urothelial carcinomas in humans and urothelial carcinoma is the most prevalent epithelial ca

110 eted delivery of cytotoxic drugs in invasive urothelial carcinoma (iUC), for which improved therapy i

111 A murine urothelial carcinoma (MB49) model expressing the male mi

112 or surgically unresectable locally advanced urothelial carcinoma, measurable disease (according to R

113 Metastatic urothelial carcinoma (mUC) has a very high mutational ra

114 3) occur in up to 80% of low-grade papillary urothelial carcinoma of the bladder (LGP-UCB) suggesting

115 p of stagnant mortality rates for metastatic urothelial carcinoma of the bladder (mUCB) at presentati

116 cal management of human cancer, including in urothelial carcinoma of the bladder (UCB).

117 Urothelial carcinoma of the bladder accounts for approxi

118 Patients with muscle-invasive urothelial carcinoma of the bladder have poor survival a

119 expression to be associated with aggressive urothelial carcinoma of the bladder, as well as increase

120 Eligible patients had histologically proven urothelial carcinoma of the bladder, pT3-pT4 disease or

121 of multimodal therapies for muscle-invasive urothelial carcinoma of the bladder.

122 undergoing radical cystectomy for cT2-3N0M0 urothelial carcinoma of the bladder.

123 newly diagnosed and histologically confirmed urothelial carcinoma of the bladder.

124 cystectomy in patients with pT3-pT4 or N+ M0 urothelial carcinoma of the bladder.

125 both nonmuscle-invasive and muscle-invasive urothelial carcinoma of the bladder.

126 Urothelial carcinoma of the renal pelvis is a deadly dis

127 we enrolled patients (age >/=18 years) with urothelial carcinoma of the renal pelvis, ureter, bladde

128 d by Aristolochia plants, is associated with urothelial carcinoma of the upper urinary tract (UUC).

129 mpound found in certain herbal medicines, in urothelial carcinomas of exposed populations.

130 Muscle-invasive urothelial carcinomas of the bladder (MIUCB) exhibit fre

131 romise for the early detection of aggressive urothelial carcinomas of the bladder.

132 ve urothelial carcinomas and 16% of invasive urothelial carcinomas of the bladder.

133 Eleven patients presented with urothelial carcinomas of the upper tract; 2 of them with

134 s associated with chronic kidney disease and urothelial carcinomas of the upper urinary tract.

135 a strong association with transitional cell (urothelial) carcinoma of the upper urinary tract.

136 e an opportunity to improve the treatment of urothelial carcinoma outside the bladder.

137 ns of epidermal growth factor (EGF) and most urothelial carcinomas overexpress EGF receptor (EGFr), r

138 patients with platinum-refractory metastatic urothelial carcinoma overexpressing PD-L1 (IC2/3).

139 tin, gemcitabine, and paclitaxel in advanced urothelial carcinoma patients and prospectively evaluate

140 Advanced urothelial carcinoma patients were screened for Her-2/ne

141 y characterized Her-2/neu status in advanced urothelial carcinoma patients.

142 ic value of the protein expressions in Ta/T1 urothelial carcinomas patients.

143 We identified a diagnostic urothelial-carcinoma pattern of 22 polypeptide masses.

144 multicenter, expansion cohort, patients with urothelial carcinoma progressing after platinum-based ch

145 patients with locally advanced or metastatic urothelial carcinoma receiving second-line treatment and

146 es of combined hazard ratio (HR) for bladder urothelial carcinoma recurrence, cancer-specific surviva

147 ), respectively; and for upper urinary tract urothelial carcinoma recurrence, CSS and OS were 2.27 (9

148 in urothelium by SV40 T antigen resulted in urothelial carcinoma, resembling human high-grade carcin

149 Immunohistochemical analysis of urothelial carcinoma samples found loss of PTEN protein

150 xome sequencing and clonality analysis of 72 urothelial carcinoma samples, including 16 matched sets

151 peptides correctly classified all samples of urothelial carcinoma (sensitivity 100% [95% CI 87-100) a

152 dentified in conventional and micropapillary urothelial carcinoma, small cell, and squamous cell carc

153 ultimately identified to have 23 upper-tract urothelial carcinomas smaller than 2 cm or carcinoma in

154 as, liposarcomas, hepatocellular carcinomas, urothelial carcinomas, squamous cell carcinomas of the t

155 between small-cell carcinoma and coexisting urothelial carcinoma suggest that both tumor components

156 lly confirmed locally advanced or metastatic urothelial carcinoma that had progressed after at least

157 treatments exist for patients with advanced urothelial carcinoma that has progressed after platinum-

158 d carcinogen exposure and developed invasive urothelial carcinomas that strongly resembled the human

159 noma and continues to shape the evolution of urothelial carcinoma throughout its lifetime.

160 Significantly, in urothelial carcinoma tissues there was increased Pyk2 lo

161 (TCR) clonality inform clinical outcomes in urothelial carcinoma treated with atezolizumab.

162 encouraging number of patients with advanced urothelial carcinoma treated with this regimen experienc

163 In the first-line treatment of metastatic urothelial carcinoma, tubulin, cytotoxic T-lymphocyte an

164 the BK virus (BKV) in the carcinogenesis of urothelial carcinoma (UC) after renal transplantation ar

165 variation in the ERBB family are frequent in urothelial carcinoma (UC) and may represent viable thera

166 enal cell carcinoma (RCC) and 3-fold risk of urothelial carcinoma (UC) compared with the general popu

167 tibility complex (MHC) class I expression in urothelial carcinoma (UC) have not been previously repor

168 fect of pre-operative renal insufficiency on urothelial carcinoma (UC) prognosis has been investigate

169 tivating mutations of PIK3CA are frequent in urothelial carcinoma (UC), no information is available o

170 eatment of patients with upper urinary tract urothelial carcinoma (UC).

171 ly predict clinical outcome in patients with urothelial carcinoma (UC).

172 treatment options for progressive metastatic urothelial carcinoma (UC).

173 ous cell carcinomas (SCC, OR = 4.90) than in urothelial carcinomas (UC, OR = 3.62).

174 in many cancer models, although its role in urothelial carcinoma (UCC) has not been extensively expl

175 Like many carcinomas, urothelial carcinoma (UroCa) is associated with chronic

176 suggested an overlap of CDC with upper tract urothelial carcinoma (UTUC), making the pathological dia

177 excision (RNU) for patients with upper tract urothelial carcinoma (UTUC).

178 cal nephroureterectomy (RNU) for upper tract urothelial carcinoma (UTUC).

179 that TGIF contributes to the progression of urothelial carcinoma via the phosphatidylinositol 3-kina

180 polypeptide from the diagnostic pattern for urothelial carcinoma was identified as fibrinopeptide A-

181 Urothelial carcinoma was the most common malignancy afte

182 confirm the role of the PI3K/AKT pathway in urothelial carcinoma, we generated mice containing biall

183 April 24, 2015, 86 patients with metastatic urothelial carcinoma were enrolled in the nivolumab mono

184 -hundred fifty-five assessable patients with urothelial carcinoma were randomized to receive either s

185 2016, 329 patients with advanced metastatic urothelial carcinoma were screened for enrolment into th

186 Fifty-two patients with advanced urothelial carcinoma were treated on one day with paclit

187 Ambulatory patients with advanced urothelial carcinoma were treated with IFX 3,750 mg/m2 a

188 affin embedded tissues from 75 patients with urothelial carcinomas were immunostained with specific a

189 In addition, basal carcinomas and prostatic urothelial carcinomas were observed.

190 Patients (aged >/=18 years) with metastatic urothelial carcinoma who had progressed after platinum-b

191 rial in patients with advanced or metastatic urothelial carcinoma who progressed during or after plat

192 th inoperable locally advanced or metastatic urothelial carcinoma whose disease had progressed after

193 patients with locally advanced or metastatic urothelial carcinoma whose disease progressed after prev

194 s with metastatic or surgically unresectable urothelial carcinoma whose disease progressed or recurre

195 e next generation of clinical management for urothelial carcinoma will witness the use of multimarker

196 Pathology revealed pathologic extravesical urothelial carcinoma, with disease in one of 25 lymph no

197 These mice developed typical renal pelvic urothelial carcinomas, with an incidence of 57.1% in mic